Literature DB >> 15459709

Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs.

Mark S Forman1, John Q Trojanowski, Virginia M-Y Lee.   

Abstract

A wide variety of neurodegenerative diseases are characterized by the accumulation of intracellular or extracellular protein aggregates. More recently, the genetic identification of mutations in familial counterparts to the sporadic disorders, leading to the development of in vitro and in vivo model systems, has provided insights into disease pathogenesis. The effect of many of these mutations is the abnormal processing of misfolded proteins that overwhelms the quality-control systems of the cell, resulting in the deposition of protein aggregates in the nucleus, cytosol and/or extracellular space. Further understanding of mechanisms regulating protein processing and aggregation, as well as of the toxic effects of misfolded neurodegenerative disease proteins, will facilitate development of rationally designed therapies to treat and prevent these disorders.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15459709     DOI: 10.1038/nm1113

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  221 in total

1.  FGF2 gene transfer restores hippocampal functions in mouse models of Alzheimer's disease and has therapeutic implications for neurocognitive disorders.

Authors:  Tomomi Kiyota; Kaitlin L Ingraham; Michael T Jacobsen; Huangui Xiong; Tsuneya Ikezu
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-31       Impact factor: 11.205

Review 2.  Polyglutamine misfolding in yeast: toxic and protective aggregation.

Authors:  Martin L Duennwald
Journal:  Prion       Date:  2011-10-01       Impact factor: 3.931

3.  Loss of tau elicits axonal degeneration in a mouse model of Alzheimer's disease.

Authors:  H N Dawson; V Cantillana; M Jansen; H Wang; M P Vitek; D M Wilcock; J R Lynch; D T Laskowitz
Journal:  Neuroscience       Date:  2010-04-29       Impact factor: 3.590

4.  (+)-Discodermolide: Total Synthesis, Construction of Novel Analogues, and Biological Evaluation.

Authors:  Amos B Smith; B Scott Freeze
Journal:  Tetrahedron       Date:  2007-01-07       Impact factor: 2.457

5.  Characterization of tau fibrillization in vitro.

Authors:  Shaohua Xu; Kurt R Brunden; John Q Trojanowski; Virginia M-Y Lee
Journal:  Alzheimers Dement       Date:  2010-03       Impact factor: 21.566

6.  Membrane lipid modification by docosahexaenoic acid (DHA) promotes the formation of α-synuclein inclusion bodies immunopositive for SUMO-1 in oligodendroglial cells after oxidative stress.

Authors:  Michael Riedel; Olaf Goldbaum; Michael Wille; Christiane Richter-Landsberg
Journal:  J Mol Neurosci       Date:  2010-08-20       Impact factor: 3.444

7.  Alpha-Synuclein Expression Restricts RNA Viral Infections in the Brain.

Authors:  Erica L Beatman; Aaron Massey; Katherine D Shives; Kristina S Burrack; Mastooreh Chamanian; Thomas E Morrison; J David Beckham
Journal:  J Virol       Date:  2015-12-30       Impact factor: 5.103

8.  Mechanistic Insights into Hsp104 Potentiation.

Authors:  Mariana P Torrente; Edward Chuang; Megan M Noll; Meredith E Jackrel; Michelle S Go; James Shorter
Journal:  J Biol Chem       Date:  2016-01-08       Impact factor: 5.157

Review 9.  Dysregulation of the autophagic-lysosomal pathway in Gaucher and Parkinson's disease.

Authors:  Caleb Pitcairn; Willayat Yousuf Wani; Joseph R Mazzulli
Journal:  Neurobiol Dis       Date:  2018-03-14       Impact factor: 5.996

10.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.

Authors:  Leslie M Shaw; Hugo Vanderstichele; Malgorzata Knapik-Czajka; Christopher M Clark; Paul S Aisen; Ronald C Petersen; Kaj Blennow; Holly Soares; Adam Simon; Piotr Lewczuk; Robert Dean; Eric Siemers; William Potter; Virginia M-Y Lee; John Q Trojanowski
Journal:  Ann Neurol       Date:  2009-04       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.